Companies › Hanmi Pharmaceutical Company
11 active drug programs in 12 registered trials: 6 Phase 2, 4 Phase 1, 2 Phase 3; Oncology, Metabolic and endocrine, Gastroenterology, Genitourinary; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HIP2602 Unclear - code-named investigational drug for erectile dysfunction | – | Phase 3 | Erectile Dysfunction | Sep 2027 |
| Efpeglenatide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes | Nov 2027 |
| HM15275 | – | Phase 2 | Obese; Type 2 Diabetes Mellitus | Jan 2027 |
| HM15136 Glucagon analog | GCGR | Phase 2 | Congenital Hyperinsulinism | May 2027 |
| HM15912 (sonefpeglutide) GLP-1 receptor agonist | GLP1R | Phase 2 | Short Bowel Syndrome | Dec 2027 |
| Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| HM17321 GLP-1 receptor agonist | – | Phase 1 | Obesity | Mar 2027 |
| BH3120 | – | Phase 1 | Advanced or Metastatic Solid Tumors | Aug 2027 |
| HM97662 EZH1/2 dual inhibitor | EZH1, EZH2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2028 |
| HM16390 | – | Phase 1 | Advanced or Metastatic Solid Tumors | Jul 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07205900 | HM15275 | Phase 2 | Obese | Metabolic and endocrine | Jan 2027 |
| NCT07219589 | HM17321 | Phase 1 | Obesity | Metabolic and endocrine | Mar 2027 |
| NCT04732416 | HM15136 | Phase 2 | Congenital Hyperinsulinism | Metabolic and endocrine | May 2027 |
| NCT06234397 | BH3120 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Aug 2027 |
| NCT07899073 | HIP2602 | Phase 3 | Erectile Dysfunction | Genitourinary | Sep 2027 |
| NCT07527650 | HM15275 | Phase 2 | Type 2 Diabetes Mellitus | Metabolic and endocrine | Oct 2027 |
| NCT07379333 | Efpeglenatide | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Nov 2027 |
| NCT04775706 | HM15912 (sonefpeglutide) | Phase 2 | Short Bowel Syndrome | Gastroenterology | Dec 2027 |
| NCT05598151 | HM97662 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Jan 2028 |
| NCT07449754 | Belvarafenib | Phase 2 | Advanced or Metastatic Melanoma | Oncology | Sep 2029 |
| NCT07449754 | Cobimetinib | Phase 2 | Advanced or Metastatic Melanoma | Oncology | Sep 2029 |
| NCT06724016 | HM16390 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Jul 2031 |
Roche Eli Lilly Novo Nordisk Pfizer Novartis AstraZeneca Hangzhou Sciwind Biosciences Day One Biopharmaceuticals Ipsen Pierre Fabre Medicament
Hangzhou Zhongmei Huadong Pharmaceutical Day One Biopharmaceuticals Shanghai Fosun Pharmaceutical Industrial Development Crinetics Pharmaceuticals Debiopharm International
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.